Evox Therapeutics wins funding to explore exosome-mediated delivery of dystrophin

Targeted delivery of dystrophin has the potential to be a highly effective treatment for Duchenne muscular dystrophy

Evox Therapeutics, an exosome therapeutics company, has announced that it has secured £655,000 in funding from Duchenne UK. The grant will be invested to support exploration of the company's exosome-based therapeutic platform to deliver either full-length dystrophin or its shorter variants in pre-clinical models of Duchenne muscular dystrophy.

Duchenne is a highly debilitating, progressive, muscle-wasting disorder caused by the lack of functional dystrophin protein, for which there is currently no cure. Delivery of dystrophin or its shorter variants to these patients has the potential to be a highly effective treatment option in Duchenne.

This work will also allow us to explore targeted delivery of exosomes to muscle which may be beneficial not only for Duchenne patients, but also ultimately for patients with other musculoskeletal diseases

Evox is engineering exosomes, the body’s natural vesicular delivery system, to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood brain barrier to deliver drugs to the central nervous system, intracellular delivery of proteins, and extra-hepatic delivery of RNA therapeutics. Evox is developing its own proprietary pipeline of exosome-based therapeutics for the treatment of rare, life-threatening diseases with significant unmet need.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “We are excited to be working with Duchenne UK on exploring a potential transformative solution to treat Duchenne patients. We will conduct research to assess the potential of our exosome drug platform to deliver functional dystrophin which is missing or defective in these patients. This work will also allow us to explore targeted delivery of exosomes to muscle which may be beneficial not only for Duchenne patients, but also ultimately for patients with other musculoskeletal diseases.”

Companies